The Impact of Modified Wheat Bran on Carbohydrate Fermentation in the Colon in Healthy and Obese Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- KU Leuven
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18 and 65 years old
- BMI between 18 and 25 kg/m² OR higher than 30 kg/m²
- Regular diet
- Not dieting
Exclusion Criteria:
- Use of antibiotics in the month preceding the study
- Diabetes Type 1 or 2
- Abdominal surgery (except from appendectomy)
- Use of medication that affects the gastrointestinal tract during the last 2 weeks prior to the study including spasmolytics, anti-diarrhoea medication, anti-constipation medication
- Use of pre- or probiotic supplements in the month preceding the study
- Chronic gastrointestinal diseases, such as inflammatory bowel disease (Crohn's disease, ulcerative colitis), irritable bowel disease…
- Pregnancy or lactation
- Blood donation in the last 3 months
- Abnormal Hb-level (Standard range between 14 and 18 g/dL for men and between 12 and 16 g/dL for women)
- Participation in clinical studies involving radiation exposure in the past year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Healthy - Wheat Bran
Wheat bran 20 g each day
|
20 g each day
|
|
Placebo Comparator: Healthy - Placebo
Placebo 20 g each day
|
20 g each day
|
|
Active Comparator: Obese - Wheat bran
Wheat bran 20 g each day
|
20 g each day
|
|
Placebo Comparator: Obese - Placebo
Placebo 20 g each day
|
20 g each day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incremental plasma short-chain fatty acid concentrations will be measured using GC-FID after an intervention with wheat bran/placebo
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in glucose levels (mg/dL)
Time Frame: 1 month
|
1 month
|
|
Changes in insulin levels (pmol/L)
Time Frame: 1 month
|
1 month
|
|
Changes in cholesterol levels (mg/dL)
Time Frame: 1 month
|
1 month
|
|
Changes in free fatty acids levels (mmol/L)
Time Frame: 1 month
|
1 month
|
|
Changes in triglyceride levels (mg/dL)
Time Frame: 1 month
|
1 month
|
|
Gut permeability using 51-Cr-EDTA
Time Frame: 1 month
|
1 month
|
|
Total gastrointestinal transit time
Time Frame: 1 month
|
1 month
|
|
Changes in gut microbiota before and after the intervention using 16S rRNA sequencing
Time Frame: 1 month
|
1 month
|
|
Changes in metabolite patterns in the feces before and after the intervention using gas chromatography coupled to mass spectrometry
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- s58346
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.